ERCC2多态性与肺癌铂类化疗敏感性的关系  

Correlation of excision repair cross-complementing group 2 polymorphisms and response to platinum-based chemotherapy in advanced non-small cell lung cancer

作　　者：李代蓉[1] 杨燕青[2] 黄新华[2] 李启英[1] 马惠文[1] 田玲[1] 王莉[1] 

机构地区：[1]重庆市肿瘤研究所肿瘤内科,重庆400030 [2]生物芯片上海国家工程研究中心,上海201203

出　　处：《中国现代医学杂志》2011年第17期2004-2007,2012,共5页China Journal of Modern Medicine

基　　金：重庆市卫生局科研基金(No:07-2-180)

摘　　要：目的研究切除修复交叉互补基因2(ERCC2)多态性与晚期非小细胞肺癌对铂类药物化疗敏感性的关系。方法应用基因芯片方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC2Asp312Asn和Lys751Gln基因型,比较不同基因型与化疗疗效的关系。结果 89例患者化疗总有效率为29.2%。ERCC2Asp312Asn和Lys751Gln基因型在化疗有效组和无效组之间的分布无差异(P>0.05)。结论 ERCC2Asp312Asn和Lys751Gln单核苷酸多态性与晚期非小细胞肺癌对铂类药物化疗敏感性无关。[Objective] To investigate the relationship between ERCC2 single nueleotide polymorphisms and sensitivity to platinum-based chemotherapy among patients with advanced non small cell lung cancer. [Methods] We used gene ehip analysis to determine the single nueleotide polymorphisms （SNPs） of excision repair eross-complemenfing group 2 （ERCC2） in DNA from peripheral lymphocytes. Totally 89 patients with NSCLC were treated with platinum -based chemotherapy, and clinical response was evaluated after 2 cycles. The association between ERCC2 gene polymorphisms and chemo-sensitivity were analyzed. [Restdts] The overall response rate was 29.2%. Chemotherapy response did not show statistically significant differences between the wild genotypes and the variant genotypes for the ERCC2 gene （P 〉0.05）. [Conclusions] ERCC2 Asp312Asn and Lys751Gln SNP may be not associated with sensitivity to platinum-based chemotherapy in advanced NSCLC patients.

关 键 词：切除修复交叉互补基因2 多态性 非小细胞肺癌 化疗 药物敏感性 

分 类 号：R730.43[医药卫生—肿瘤] R734.2[医药卫生—临床医学]